Acute heart failure and adverse events associated with the presence of renal dysfunction and hyperkalaemia. EAHFE- renal dysfunction and hyperkalaemia.
Eur J Intern Med. 2019 Jul 20;:
Authors: Jacob J, Llauger L, Herrero-Puente P, Martín-Sánchez FJ, Llorens P, Roset A, Gil V, Fuentes M, Lucas-Imbernón FJ, Miró Ò, ICASEMES-Research Group, Gil C, Alonso H, Pérez-Llantada E, Llopis-García G, Santos-Matallana MC, Barrenechea-Moxó MLD, Salgado-Pérez L, Escoda R, Xipell C, Sánchez C, Gaytan JM, Pérez-Durá MJ, Salvo E, Pavón J, Noval A, Torres JM, López-Grima ML, Valero A, Juan MÁ, Aguirre A, Pedragosa MA, Mínguez-Masó S, Alonso MI, Ruiz F, Franco JM, Mecina AB, Tost J, Berenguer M, Donea R, Sánchez-Ramón S, Carbajosa-Rodríguez V, Piñera P, Sánchez-Nicolás JA, Garate RT, Alquézar-Arbé A, Rizzi MA, Herrera S, Roset A, Cabello I, Haro A, Richard F, Álvarez-Perez JM, López-Diez MP, Vázquez-Álvarez J, Prieto-García B, García MG, González MS, Javaloyes P, Marquina V, Jiménez I, Hernández N, Brouzet B, Espinosa B, Andueza JA, Romero R, Ruíz M, Calvache R, Serralta MTL, Jave LEC, Arriaga BA, Bergua BS, Mojarro EM, Jiménez BSA, Bécquer LT, Burillo G, García LL, LaSalle GC, Urbano CA, Soto ABG, Padial ED, Ferrer ES, Garrido JM, Lucas-Imbernón FJ, Gaya R, Bibiano C, Mir M, Rodríguez B, Carballo JL, Rodríguez-Adrada E, Miranda BR
OBJECTIVE: To study the outcomes of patients with acute heart failure (AHF) presenting renal dysfunction (RD) or hyperkalaemia (Hk) alone or in combination.
METHOD: We analysed the data of the EAHFE registry, a multicentre, non interventionist cohort with prospective follow-up of patients with AHF. Four groups were defined based on the presence or not of RD or Hk alone or in combination. The primary endpoint was 30-day all-cause mortality.
RESULTS: A total of 11,935 of the 13,791 patients included in the EAHFE registry were analysed. Of these, 5088 (42.6%) did not have RD or Hk (NoRD-NoHk), 150 (1.3%) had no RD but had Hk (NoRD-Hk), 6012 (50.4%) had RD but not Hk (RD-NoHk) and 685 (5.7%) had both RD and Hk (RD-Hk). Thirty-day all-cause mortality was greatest in the RD-Hk group with an adjusted Hazard Ratio (HR) of 2.44 (confidence interval 95% [CI95%] 1.67-3.55; p < 0.001) and in the RD-NoHk group with an adjusted HR of 1.34 (CI95% 1.04-1.71; p = 0.022). There were no significant differences in in-hospital mortality and reconsultation at 30 days for HF. For the combined endpoint of 30-day all-cause mortality the adjusted HR was 1.33 (CI95% 1.04-1.70); (p = 0.021) for the RD-Hk group.
CONCLUSIONS: The association of 30-day all-cause mortality with the presence of RD and Hk in patients presenting AHF at admission is greater than in those without this combination.
PMID: 31331793 [PubMed - as supplied by publisher]